Drug Profile

COM 101

Alternative Names: COM-101; CS-004

Latest Information Update: 28 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of British Columbia
Developer Commense
Class Antiasthmatics; Bacteria; Immunotherapies; Skin disorder therapies
Mechanism of Action Bacteria replacements; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Asthma; Atopic dermatitis

Most Recent Events

28 Jul 2022 No recent reports of development identified for preclinical development in Atopic-dermatitis(Prevention) in USA
28 Jun 2021 No recent reports of development identified for preclinical development in Asthma(Prevention) in USA
18 Jun 2018 Commense has patent applications for microbiome based therapy worldwide (PureTech pipeline, June 2018)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com